I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for DexCom in a research report issued ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Leerink Partnrs issued their Q1 2025 EPS estimates for Blueprint Medicines in a research note issued on Thursday, February ...

NeuroPace, Inc. (Nasdaq: NPCE) today announced the completion of its previously announced underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $10.00 per ...

Goldman Sachs, Leerink and Evercore ISI acted as joint book running managers for the offering.Discover the Best Stocks and Maximize Your ...

The trial data, which was reported on February 18, 2025, also suggested potential cardiac benefits from the therapy. The company mentioned that SGT-003 has been well-tolerated with no serious adverse ...

The gig mobility industry is facing new challenges in 2025, as consumer prices continue to rise while consumers push back against fare increases. At the same time, driver wages are stagnating, with ...

NetraMark Holdings Inc. (the "Company" or "NetraMark")  a generative AI software leader in clinical trial analytics, announces that it will present new data supporting its mathematically augmented ...